Latest News | Lupin Gets USFDA Nod for Generic Antibacterial Drug

New Delhi, Mar 15 (PTI) Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat bacterial infections, in America.

The company has received approval from the USFDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement.

Also Read | Indian States and Their Formation Dates: Maharashtra Din, Bihar Day, Karnataka Rajyotsava, Kerala Piravi & More - Marking Celebrations of Statehood Days.

The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added.

The product will be manufactured at its Nagpur facility, Lupin said.

Also Read | AP TET Exam Results 2024: Final Answer Key of Andhra Pradesh Teacher Eligibility Test Examination Released at aptet.apcfss.in, Main Results To Be Declared Soon.

Doxycycline for Injection USP is indicated to reduce the development of drug-resistant bacteria.

As per the IQVIA MAT January 2024 data, Doxycycline for Injection USP had estimated annual sales of USD 47 million in the US market.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)